At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 115 enrolled
Drug / intervention
Lipoic acid +1 moredrug
Likely dose
Lipoic acid 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lipoic Acid for the Treatment of Progressive Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating Lipoic acid and Placebo for Multiple Sclerosis. Completed, enrolled 115 participants across 11 sites in 2 countries.
Detailed Summary
The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartAug 2018
Primary CompletionDec 2023
Study CompletionJun 2024
TodayJul 2026
First PostedMay 19, 2017
Enrollment StartAug 17, 2018
Primary CompletionDec 31, 2023
Study CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 9.1 years ago
Interventions
Lipoic aciddrug
1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
Placebodrug
The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation